文献速递眼底病与葡萄膜炎神经眼科

全视网膜光凝与雷珠单抗治疗增殖性糖尿病视网膜病变:随机临床试验中视盘周围视网膜神经纤维层厚度的比较

PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial.
PubMed 文献 · Retina · 2019-01-01

本随机临床试验比较了增殖性糖尿病视网膜病变患眼接受玻璃体腔注射雷珠单抗或全视网膜光凝后视网膜神经纤维层(RNFL)厚度的变化。2年时,雷珠单抗组平均RNFL厚度变化为-10.9±11.7 μm,全视网膜光凝组为-4.3±11.6 μm,差异为-4.9 μm(95%CI [-7.2 μm至-2.6 μm];P<0.001)。RNFL厚度变化与视野和中心亚区厚度的相关性提示,雷珠单抗组的RNFL变薄可能源于水肿减轻而非轴突丢失。

要点

  • 2年时雷珠单抗组平均RNFL厚度变化为-10.9±11.7 μm,全视网膜光凝组为-4.3±11.6 μm,差异-4.9 μm(95%CI [-7.2 μm至-2.6 μm];P<0.001)。
  • 雷珠单抗组RNFL厚度变化与60-4 Humphrey视野平均偏差的相关性为-0.27(P=0.07),全视网膜光凝组为+0.33(P=0.035)。
  • 雷珠单抗组RNFL厚度变化与中心亚区厚度的相关性为+0.63(P<0.001),全视网膜光凝组为+0.34(P=0.005)。

核心结论

  • 2年时,雷珠单抗治疗眼较全视网膜光凝治疗眼出现更明显的RNFL变薄。
  • RNFL厚度变化与视野及中心亚区厚度的相关性提示,雷珠单抗相关的RNFL变薄可能源于水肿减轻而非轴突丢失。

研究设计与样本

  • 随机临床试验,纳入增殖性糖尿病视网膜病变患眼,随机分配至雷珠单抗组或全视网膜光凝组。
  • 共分析120名参与者的146只眼;雷珠单抗组74只眼,全视网膜光凝组66只眼。
  • 基线及每年进行谱域光学相干断层扫描RNFL成像、黄斑成像和自动静态视野检查(Humphrey 60-4算法)。

主要发现

  • 2年时,雷珠单抗组平均RNFL厚度变化为-10.9±11.7 μm,全视网膜光凝组为-4.3±11.6 μm,差异为-4.9 μm(95%CI [-7.2 μm至-2.6 μm];P<0.001)。
  • 雷珠单抗组RNFL厚度变化与60-4 Humphrey视野平均偏差的相关性为-0.27(P=0.07),全视网膜光凝组为+0.33(P=0.035)。
  • 雷珠单抗组RNFL厚度变化与中心亚区厚度的相关性为+0.63(P<0.001),全视网膜光凝组为+0.34(P=0.005)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Compare changes in retinal nerve fiber layer (RNFL) thickness between eyes assigned to intravitreous ranibizumab or panretinal photocoagulation and assess correlations between changes in RNFL and visual field sensitivity and central subfield thickness. METHODS: Eyes with proliferative diabetic retinopathy were randomly assigned to ranibizumab or panretinal photocoagulation. Baseline and annual follow-up spectral domain optical coherence tomography RNFL imaging, optical coherence tomography macular imaging, and automated static perimetry (Humphrey visual field 60-4 algorithm) were performed. RESULTS: One hundred forty-six eyes from 120 participants were analyzed. At 2 years, for the ranibizumab (N = 74) and panretinal photocoagulation (N = 66) groups, respectively, mean change in average RNFL thickness was -10.9 ± 11.7 μm and -4.3 ± 11.6 μm (difference, -4.9 μm; 95% confidence interval [-7.2 μm to -2.6 μm]; P < 0.001); the correlation between change in RNFL thickness and 60-4 Humphrey visual field mean deviation was -0.27 (P = 0.07) and +0.33 (P = 0.035); the correlation between change in RNFL thickness and central subfield thickness was +0.63 (P < 0.001) and +0.34 (P = 0.005), respectively. CONCLUSION: At 2 years, eyes treated with ranibizumab had greater RNFL thinning than eyes treated with panretinal photocoagulation. Correlations between changes in RNFL thickness, visual field, and central subfield thickness suggest that the decrease in RNFL thickness with ranibizumab is likely due to decreased edema rather than loss of axons.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Jampol LM, Odia I, Glassman AR, et al. PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial. Retina. 2019. PMID: 29135802. doi:10.1097/IAE.0000000000001909

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。